Download Files:
Atreleuton
$314
Only 1000 item(s) left in stock.
Products Details
Product Description
– Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation[1][2][3]. Atreleuton is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Web ID
– HY-117853
Shipping
– Room temperature
Applications
– Neuroscience-Neuromodulation
Molecular Formula
– C16H15FN2O2S
References
– [1]VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease. VIA Pharmaceuticals, Inc.|[2]Reid JJ, et al. ABT-761 (Abbott). Curr Opin Investig Drugs. 2001 Jan;2(1):68-71.|[3]Bell RL, et al. ABT-761 attenuates bronchoconstriction and pulmonary inflammation in rodents. J Pharmacol Exp Ther. 1997 Mar;280(3):1366-73.
CAS Number
– 154355-76-7
Molecular Weight
– 318.37
SMILES
– O=C(N)N([C@H](C)C#CC1=CC=C(CC2=CC=C(F)C=C2)S1)O
Clinical Information
– Phase 2
Research Area
– Cardiovascular Disease
Solubility
– 10 mM in DMSO
Target
– Lipoxygenase
Isoform
– 5-LOX
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
